OverviewSuggest Edit

CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform.

TypePublic
Founded2013
HQZug, CH
Websitecrisprtx.com
Employee Ratings3.3

Latest Updates

Employees (est.) (Dec 2019)304(+62%)
Revenue (FY, 2019)$289.6 M(+9170%)
Share Price (Jan 2021)$198.3
Cybersecurity ratingAMore

Key People/Management at CRISPR Therapeutics

Samarth Kulkarni

Samarth Kulkarni

Chief Executive Officer & Director
Steve Caffé

Steve Caffé

Head of Regulatory Affairs
Shaun Foy

Shaun Foy

Co-Founder
Tony Ho

Tony Ho

Head of Research and Development
Stephen Kennedy

Stephen Kennedy

Head of Technical Operations
James Kasinger

James Kasinger

General Counsel and Secretary to the Board of Directors
Show more

CRISPR Therapeutics Office Locations

CRISPR Therapeutics has offices in Zug, Cambridge, San Francisco and Greater London
Zug, CH (HQ)
Baarerstrasse 14/V8
Greater London, GB
85 Tottenham Court Rd
Cambridge, MA, US
610 Main St
San Francisco, CA, US
455 Mission Bay Boulevard South, San Francisco
Show all (4)

CRISPR Therapeutics Financials and Metrics

CRISPR Therapeutics Revenue

CRISPR Therapeutics's revenue was reported to be $289.59 m in FY, 2019
USD

Revenue (Q3, 2020)

148.0k

Net income (Q3, 2020)

(92.4m)

EBIT (Q3, 2020)

(92.4m)

Market capitalization (19-Jan-2021)

14.1b

Closing stock price (19-Jan-2021)

198.3

Cash (30-Sept-2020)

1.0b

EV

13.1b
CRISPR Therapeutics's current market capitalization is $14.1 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

5.2m41.0m3.1m289.6m

General and administrative expense

31.1m35.8m48.3m63.5m

R&D expense

42.2m69.8m113.8m179.4m

Operating expense total

73.3m105.6m162.1m242.9m
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

1.5m2.7m3.6m2.4m1.4m1.1m563.0k328.0k318.0k211.9m157.0k44.0k148.0k

General and administrative expense

4.1m8.6m7.8m8.1m8.8m12.7m10.2m14.9m15.8m15.5m19.6m21.4m21.5m

R&D expense

12.1m14.8m17.1m17.8m19.5m25.6m39.8m33.8m39.5m57.2m54.2m59.4m71.0m

Operating expense total

16.2m23.4m24.9m26.0m28.4m38.4m50.0m48.8m55.3m72.8m73.7m80.7m92.5m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

315.5m239.8m456.6m943.8m

Accounts Receivable

3.2m2.6m88.0k99.0k

Prepaid Expenses

1.5m6.0m9.7m43.7m

Current Assets

320.2m248.4m466.4m987.5m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(23.2m)(68.4m)(165.0m)66.9m

Depreciation and Amortization

925.0k3.0m3.5m4.7m

Accounts Payable

3.9m(831.0k)12.1m5.0m

Cash From Operating Activities

(55.3m)(70.1m)(96.2m)56.7m
USDQ3, 2016

Financial Leverage

-4.5 x
Show all financial metrics

CRISPR Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

CRISPR Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

CRISPR Therapeutics Online and Social Media Presence

Embed Graph

CRISPR Therapeutics News and Updates

Thinking about trading options or stock in Axon Enterprise, Tilray, Pfizer, Crispr Therapeutics, or General Motors?

NEW YORK, Jan. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAXN, TLRY, PFE, CRSP, and GM. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Thinking about trading options or stock in Crispr Therapeutics, GameStop, Moderna, Tesla, or FuelCell Energy?

NEW YORK, Dec. 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRSP, GME, MRNA, TSLA, and FCEL. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV

-Funding from the Bill & Melinda Gates Foundation will support research to enable CRISPR/Cas9-based therapies for HIV that can benefit patients worldwide-

CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta Thalassemia

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the companies will host an investor webcast on December 9, 2020 at 8:00 a.m. ET to review clinical data…

CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to partici…
Show more

CRISPR Therapeutics Blogs

CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

ZUG, Switzerland and CAMBRIDGE, Mass. , Nov. 24, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to

CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference

CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference william.meady@… Thu, 09/03/2020 - 08:02 CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference September 3, 2020 at 8:00 AM EDT This release is a…

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results

-Dosing re-initiated in clinical trials of CTX001™ for patients with severe hemoglobinopathies- - CTX001 has received orphan drug designation from the U.S. FDA for sickle cell disease (SCD)- -Expands regenerative medicine portfolio through a collaboration with University Health Network (UHN),

CRISPR Therapeutics Announces Proposed Offering of Common Shares

ZUG, Switzerland and CAMBRIDGE, Mass. , June 29, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of

CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility

-State-of-the-art facility to be located in Framingham , Massachusetts - -New facility intended to support clinical and commercial production of investigational cell therapies- ZUG, Switzerland and CAMBRIDGE, Mass. , June 25, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics  (Nasdaq: CRSP), a

CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting

CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting Content Import Fri, 05/15/2020 - 08:31 CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting May 15, 2020…
Show more

CRISPR Therapeutics Frequently Asked Questions

  • When was CRISPR Therapeutics founded?

    CRISPR Therapeutics was founded in 2013.

  • Who are CRISPR Therapeutics key executives?

    CRISPR Therapeutics's key executives are Samarth Kulkarni, Steve Caffé and Shaun Foy.

  • How many employees does CRISPR Therapeutics have?

    CRISPR Therapeutics has 304 employees.

  • What is CRISPR Therapeutics revenue?

    Latest CRISPR Therapeutics annual revenue is $289.6 m.

  • What is CRISPR Therapeutics revenue per employee?

    Latest CRISPR Therapeutics revenue per employee is $952.6 k.

  • Who are CRISPR Therapeutics competitors?

    Competitors of CRISPR Therapeutics include Reborna Biosciences, Chimeron Bio and Ichor Therapeutics.

  • Where is CRISPR Therapeutics headquarters?

    CRISPR Therapeutics headquarters is located at Baarerstrasse 14/V8, Zug.

  • Where are CRISPR Therapeutics offices?

    CRISPR Therapeutics has offices in Zug, Cambridge, San Francisco and Greater London.

  • How many offices does CRISPR Therapeutics have?

    CRISPR Therapeutics has 4 offices.